Stable Crystalline Forms for HBV Core Protein Assembly Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infections, such as nucleos(t)ide analogs and interferon α, either fail to eliminate the infection or have severe side effects, leaving a significant need for more effective therapies.
Innovation Solution
Development of novel crystalline forms of a certain compound, characterized by specific XRPD and DSC patterns, which can be used to create pharmaceutical compositions for treating HBV infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleos(t)ide analogs are used to treat HBV infections, then virus production is suppressed, but the infection is not eliminated and drug resistance may emerge
Solution Approach 1:
The patent changes the mechanism of action from nucleos(t)ide analogs (which suppress virus production) to a compound that targets and disrupts core protein assembly, fundamentally altering how the virus is attacked and potentially enabling cure while maintaining suppression
Solution Approach 2:
The invention extracts and targets a specific critical component (core protein assembly) of the HBV structure, separating the suppression function from the elimination function to achieve both virus control and potential cure simultaneously
2Reliability
If interferon α is used to treat HBV infections, then sustained clinical response is achieved in some patients, but severe side effects and poor tolerability occur
Solution Approach 1:
The patent introduces a new intermediary compound that mediates the treatment effect, replacing interferon α as the primary active agent and thereby eliminating the severe side effects associated with interferon while maintaining therapeutic efficacy through a different mechanism
Solution Approach 2:
The invention converts the harmful side effects of interferon therapy into a benefit by using a completely different mechanism of action (core protein assembly disruption) that achieves sustained response without the harmful effects, turning a harmful treatment into a beneficial one
3Duration of action of stationary object
If nucleos(t)ide analogs are used for long-term treatment, then virus production is continuously suppressed, but patients must remain on treatment to avoid viral rebound
Solution Approach 1:
The patent applies preliminary action by targeting and disrupting core protein assembly before complete viral replication occurs, creating a therapeutic window that allows for finite treatment duration while preventing viral rebound through early intervention in the viral life cycle
Data Source
AI summary
The present disclosure generally relates to novel crystalline forms of a certain compound which are useful as modulators of hepatitis B virus core protein assembly. The present disclosure also relates to identifying suitable solid forms with promising solid state properties for clinical development. The solid state forms disclosed may be used in the manufacture of drug products which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a stable crystalline form which may be useful for treating viral infections, such as hepatitis B.